헬스케어 콜드체인 제3자 물류 시장 규모, 점유율, 동향 분석 보고서 : 서비스별, 제품별, 온도 범위별, 최종 용도별, 지역별, 부문별 예측(2026-2033년)

Healthcare Cold Chain Third Party Logistics Market Summary

The global healthcare cold chain third party logistics market size was valued at USD 45.76 billion in 2025 and is projected to reach USD 83.40 billion by 2033, growing at a CAGR of 7.74% from 2026 to 2033. The rising demand for temperature-sensitive pharmaceutical products, stringent global regulations for pharmaceutical storage and distribution and expansion of global pharmaceutical distribution networks.

The growing global demand for vaccines, biologics, cell and gene therapies, and specialty drugs is significantly increasing reliance on cold chain logistics. Biologics, including monoclonal antibodies, gene therapies, and recombinant proteins, require stringent temperature control-typically between 2°C and 8°C, with some requiring ultra-low storage at -70°C or lower-to maintain their efficacy. As more temperature-sensitive products enter the market, pharmaceutical companies require highly specialized storage, packaging, and distribution systems to maintain product efficacy. This rise in biologics and high-value therapies directly drives the need for advanced 3PL providers capable of offering end-to-end temperature control, real-time monitoring, and regulatory compliance. As a result, healthcare companies outsource logistics to experienced cold chain specialists to reduce risk, ensure product quality, and meet global distribution timelines, thereby accelerating the expansion of the healthcare cold chain 3PL market.

In addition, strict guidelines from government bodies such as FDA, EMA, and WHO require exact temperature management, verified transportation protocols, and thorough documentation for the distribution of pharmaceuticals. These regulatory demands create difficulties and expenses for manufacturers attempting to handle logistics on their own. As a result, companies rely on third-party logistics providers that have validated equipment, comply with GDP standards, and utilize advanced monitoring technologies. This transition ensures ongoing compliance with regulations, minimizes the risk of product loss or recalls, and strengthens the integrity of the supply chain.

Furthermore, as pharmaceutical companies expand their presence in emerging markets, the demand for dependable temperature-controlled distribution increases. These areas frequently face challenges such as insufficient cold storage facilities, fragmentated transportation systems, and inconsistent regulatory frameworks. The growth of cell and gene therapies is driving demand for ultra-low and cryogenic cold chain capacity. For instance, Cencora will expand its services in 500,000-sq-ft Texas 3PL facility will greatly expand controlled, refrigerated, frozen, and cryogenic storage capabilities. Thus, pharmaceutical manufacturers are turning to specialized third-party logistics (3PL) providers that possess well-established global networks, validated cold chain processes, and insights into local markets. This trend towards outsourcing helps minimize operational risks, guarantee consistent delivery, and preserve product integrity over long distances and varying climates. The expanding geographic distribution of healthcare products directly enhances the need for sophisticated 3PL cold chain services, thereby driving market growth.

Global Healthcare Cold Chain Third Party Logistics Market Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global healthcare cold chain third party logistics market based on service, product, temperature range, end use, and region.

• Service Outlook (Revenue, USD Million, 2021 - 2033)
• Transportation
  • Air Freight
  • Sea Freight
  • Overland
• Warehousing & Storage
• Packaging Solutions
• Monitoring & Visibility Solutions
• Inventory Management
• Others
• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Biopharmaceuticals
• Pharmaceuticals
• Medical Device
• Others
• Temperature Range Outlook (Revenue, USD Million, 2021 - 2033)
• Frozen
• Ultra-frozen/Deep-Frozen
• Cryogenic
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Pharmaceutical & Biopharmaceutical Companies
• Medical Device Companies
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Thailand
  • South Korea
  • Australia
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait
  • Oman
  • Qatar

Table of Contents

Chapter 1. Research Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Service
  • 1.2.2. Product
  • 1.2.3. Temperature Range
  • 1.2.4. End Use
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
• 1.5. Information Or Data Analysis
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity Flow Analysis
  • 1.7.2. Top-Down Analysis
  • 1.7.3. Botton-Up Approach
  • 1.7.4. Multivariate Analysis
• 1.8. List of Secondary Sources
• 1.9. List of Abbreviations
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Healthcare Cold Chain Third Party Logistics Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Rising Demand for Temperature-Sensitive Pharmaceutical Products,
    • 3.2.1.2. Stringent Global Regulations for Pharmaceutical Storage and Distribution
    • 3.2.1.3. Expansion Of Global Pharmaceutical Distribution Networks
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. High Infrastructure and Compliance Costs
    • 3.2.2.2. Limited Skilled Workforce and Temperature Excursion Risks
• 3.3. Technology Landscape
• 3.4. Pricing Model Analysis
• 3.5. Tariff Impact Analysis
• 3.6. Value Chain Analysis
  • 3.6.1. Supply Trends
  • 3.6.2. Demand Trends
• 3.7. Market Analysis Tools
  • 3.7.1. Porter's Five Force Analysis
  • 3.7.2. PESTEL by SWOT Analysis

Chapter 4. Healthcare Cold Chain Third Party Logistics Market: Service Estimates & Trend Analysis

• 4.1. Healthcare Cold Chain Third Party Logistics Market, By Service: Segment Dashboard
• 4.2. Healthcare Cold Chain Third Party Logistics Market, By Service: Movement Analysis
• 4.3. Healthcare Cold Chain Third Party Logistics Market Estimates & Forecasts, By Service, 2021 - 2033
• 4.4. Transportation
  • 4.4.1. Transportation Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4.2. Air Freight
    • 4.4.2.1. Air Freight Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4.3. Sea Freight
    • 4.4.3.1. Sea Freight Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4.4. Overland
    • 4.4.4.1. Overland Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.5. Warehousing & Storage
  • 4.5.1. Warehousing & Storage Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.6. Packaging Solutions
  • 4.6.1. Packaging Solutions Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.7. Monitoring & Visibility Solutions
  • 4.7.1. Monitoring & Visibility Solutions Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.8. Inventory Management
  • 4.8.1. Inventory Management Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.9. Others
  • 4.9.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Healthcare Cold Chain Third Party Logistics Market: Product Estimates & Trend Analysis

• 5.1. Healthcare Cold Chain Third Party Logistics Market, By Product: Segment Dashboard
• 5.2. Healthcare Cold Chain Third Party Logistics Market, By Product: Movement Analysis
• 5.3. Healthcare Cold Chain Third Party Logistics Market Estimates & Forecasts, By Product, 2021 - 2033
• 5.4. Biopharmaceuticals
  • 5.4.1. Biopharmaceuticals Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. Pharmaceuticals
  • 5.5.1. Pharmaceuticals Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.6. Medical Device
  • 5.6.1. Medical Device Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.7. Others
  • 5.7.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Healthcare Cold Chain Third Party Logistics Market: Temperature Range Estimates & Trend Analysis

• 6.1. Healthcare Cold Chain Third Party Logistics Market, By Temperature Range: Segment Dashboard
• 6.2. Healthcare Cold Chain Third Party Logistics Market, By Temperature Range: Movement Analysis
• 6.3. Healthcare Cold Chain Third Party Logistics Market Estimates & Forecasts, By Temperature Range, 2021 - 2033
• 6.4. Frozen
  • 6.4.1. Frozen Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Ultra-frozen/Deep-Frozen
  • 6.5.1. Ultra-frozen/Deep-Frozen Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. Cryogenic
  • 6.6.1. Cryogenic Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Healthcare Cold Chain Third Party Logistics Market: End Use Estimates & Trend Analysis

• 7.1. Healthcare Cold Chain Third Party Logistics Market, By End Use: Segment Dashboard
• 7.2. Healthcare Cold Chain Third Party Logistics Market, By End Use: Movement Analysis
• 7.3. Healthcare Cold Chain Third Party Logistics Market Estimates & Forecasts, By End Use, 2021 - 2033
• 7.4. Pharmaceutical & Biopharmaceutical Companies
  • 7.4.1. Pharmaceutical & Biopharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.5. Medical Device Companies
  • 7.5.1. Medical Device Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.6. Others
  • 7.6.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Healthcare Cold Chain Third Party Logistics Market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Dashboard
• 8.2. Regional Market Share Analysis, 2025 & 2033
• 8.3. North America
  • 8.3.1. North America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.3.2. U.S
    • 8.3.2.1. Key Country Dynamics
    • 8.3.2.2. Competitive Scenario
    • 8.3.2.3. Regulatory Framework
    • 8.3.2.4. U.S. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.3.3. Canada
    • 8.3.3.1. Key Country Dynamics
    • 8.3.3.2. Competitive Scenario
    • 8.3.3.3. Regulatory Framework
    • 8.3.3.4. Canada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.3.4. Mexico
    • 8.3.4.1. Key Country Dynamics
    • 8.3.4.2. Competitive Scenario
    • 8.3.4.3. Regulatory Framework
    • 8.3.4.4. Mexico Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.4. Europe
  • 8.4.1. Europe Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.2. UK
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Competitive Scenario
    • 8.4.2.3. Regulatory Framework
    • 8.4.2.4. UK Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.3. Germany
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Competitive Scenario
    • 8.4.3.3. Regulatory Framework
    • 8.4.3.4. Germany Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.4. France
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Competitive Scenario
    • 8.4.4.3. Regulatory Framework
    • 8.4.4.4. France Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.5. Italy
    • 8.4.5.1. Key Country Dynamics
    • 8.4.5.2. Competitive Scenario
    • 8.4.5.3. Regulatory Framework
    • 8.4.5.4. Italy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.6. Spain
    • 8.4.6.1. Key Country Dynamics
    • 8.4.6.2. Competitive Scenario
    • 8.4.6.3. Regulatory Framework
    • 8.4.6.4. Spain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.7. Denmark
    • 8.4.7.1. Key Country Dynamics
    • 8.4.7.2. Competitive Scenario
    • 8.4.7.3. Regulatory Framework
    • 8.4.7.4. Denmark Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.8. Sweden
    • 8.4.8.1. Key Country Dynamics
    • 8.4.8.2. Competitive Scenario
    • 8.4.8.3. Regulatory Framework
    • 8.4.8.4. Sweden Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.9. Norway
    • 8.4.9.1. Key Country Dynamics
    • 8.4.9.2. Competitive Scenario
    • 8.4.9.3. Regulatory Framework
    • 8.4.9.4. Norway Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.5. Asia Pacific
  • 8.5.1. Asia Pacific Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.2. Japan
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Competitive Scenario
    • 8.5.2.3. Regulatory Framework
    • 8.5.2.4. Japan Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.3. China
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Competitive Scenario
    • 8.5.3.3. Regulatory Framework
    • 8.5.3.4. China Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.4. India
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Competitive Scenario
    • 8.5.4.3. Regulatory Framework
    • 8.5.4.4. India Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.5. Thailand
    • 8.5.5.1. Key Country Dynamics
    • 8.5.5.2. Competitive Scenario
    • 8.5.5.3. Regulatory Framework
    • 8.5.5.4. Thailand Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.6. South Korea
    • 8.5.6.1. Key Country Dynamics
    • 8.5.6.2. Competitive Scenario
    • 8.5.6.3. Regulatory Framework
    • 8.5.6.4. South Korea Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.7. Australia
    • 8.5.7.1. Key Country Dynamics
    • 8.5.7.2. Competitive Scenario
    • 8.5.7.3. Regulatory Framework
    • 8.5.7.4. Australia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.6. Latin America
  • 8.6.1. Latin America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.2. Brazil
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Competitive Scenario
    • 8.6.2.3. Regulatory Framework
    • 8.6.2.4. Brazil Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.3. Argentina
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Competitive Scenario
    • 8.6.3.3. Regulatory Framework
    • 8.6.3.4. Argentina Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.7. MEA
  • 8.7.1. MEA Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.2. South Africa
    • 8.7.2.1. Key Country Dynamics
    • 8.7.2.2. Competitive Scenario
    • 8.7.2.3. Regulatory Framework
    • 8.7.2.4. South Africa Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.3. Saudi Arabia
    • 8.7.3.1. Key Country Dynamics
    • 8.7.3.2. Competitive Scenario
    • 8.7.3.3. Regulatory Framework
    • 8.7.3.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.4. UAE
    • 8.7.4.1. Key Country Dynamics
    • 8.7.4.2. Competitive Scenario
    • 8.7.4.3. Regulatory Framework
    • 8.7.4.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.5. Kuwait
    • 8.7.5.1. Key Country Dynamics
    • 8.7.5.2. Competitive Scenario
    • 8.7.5.3. Regulatory Framework
    • 8.7.5.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.6. Oman
    • 8.7.6.1. Key Country Dynamics
    • 8.7.6.2. Competitive Scenario
    • 8.7.6.3. Regulatory Framework
    • 8.7.6.4. Oman Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.7. Qatar
    • 8.7.7.1. Key Country Dynamics
    • 8.7.7.2. Competitive Scenario
    • 8.7.7.3. Regulatory Framework
    • 8.7.7.4. Qatar Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Key Participant Categorization
  • 9.1.1. Market Leaders
  • 9.1.2. Emerging Players
• 9.2. Market Share/Assessment Analysis, 2025 (Heat Map Analysis)
• 9.3. Company Profiles
  • 9.3.1. Cardinal Health
    • 9.3.1.1. Company Overview
    • 9.3.1.2. Financial Performance
    • 9.3.1.3. Service Benchmarking
    • 9.3.1.4. Strategic Initiatives
  • 9.3.2. DHL
    • 9.3.2.1. Company Overview
    • 9.3.2.2. Financial Performance
    • 9.3.2.3. Service Benchmarking
    • 9.3.2.4. Strategic Initiatives
  • 9.3.3. Agility
    • 9.3.3.1. Company Overview
    • 9.3.3.2. Financial Performance
    • 9.3.3.3. Service Benchmarking
    • 9.3.3.4. Strategic Initiatives
  • 9.3.4. SF Express
    • 9.3.4.1. Company Overview
    • 9.3.4.2. Financial Performance
    • 9.3.4.3. Service Benchmarking
    • 9.3.4.4. Strategic Initiatives
  • 9.3.5. Kinesis
    • 9.3.5.1. Company Overview
    • 9.3.5.2. Financial Performance
    • 9.3.5.3. Service Benchmarking
    • 9.3.5.4. Strategic Initiatives
  • 9.3.6. UPS
    • 9.3.6.1. Company Overview
    • 9.3.6.2. Financial Performance
    • 9.3.6.3. Service Benchmarking
    • 9.3.6.4. Strategic Initiatives
  • 9.3.7. Barrett Distribution Centers
    • 9.3.7.1. Company Overview
    • 9.3.7.2. Financial Performance
    • 9.3.7.3. Service Benchmarking
    • 9.3.7.4. Strategic Initiatives
  • 9.3.8. AmerisourceBergen
    • 9.3.8.1. Company Overview
    • 9.3.8.2. Financial Performance
    • 9.3.8.3. Service Benchmarking
    • 9.3.8.4. Strategic Initiatives
  • 9.3.9. DB Schenker
    • 9.3.9.1. Company Overview
    • 9.3.9.2. Financial Performance
    • 9.3.9.3. Service Benchmarking
    • 9.3.9.4. Strategic Initiatives
  • 9.3.10. FedEx
    • 9.3.10.1. Company Overview
    • 9.3.10.2. Financial Performance
    • 9.3.10.3. Service Benchmarking
    • 9.3.10.4. Strategic Initiatives
  • 9.3.11. KUEHNE + NAGEL
    • 9.3.11.1. Company Overview
    • 9.3.11.2. Financial Performance
    • 9.3.11.3. Service Benchmarking
    • 9.3.11.4. Strategic Initiatives